The Future of Real-World Evidence: Pharma’s Next Moves

Today, there are clear signs that the biopharmaceutical industry is facing a quiet yet potentially damaging force: compressive disruption. However, future-focused biopharma companies have found a way to deliver exceptional growth amidst compressive disruption: by embracing New Science, an ever-evolving combination of the best in science and health technology that is filling unmet need and raising the standard of care. Accenture research finds that leaders in New Science are investing 6-7x more in digital, data and genomics compared to their peers.

In the realm of DNA sequencing, technology developers contribute to advancement in important ways, by building increasingly fast-moving tools that untangle the intricacies of the human genome, and by constructing analytics platforms to wade through the resulting mountains of genetic data.

Companies often experience regulatory challenges during an inspection of aging facilities, requiring them to initiate projects to optimize product protection and updating to current standards for classified areas for biopharma manufacturing. For a long time, the company response has been to improve the existing classified areas or maybe even upgrading to a higher grade of classification. However, it may be more appropriate, and improve product protection, to instead implement the use of closed system processes and downgrade room classification during these facility renovation projects. If closed systems are fully utilized, then a CNC space can be used. As well as reducing the complexity of operations, this will reduce capital and operating costs.

Many global pharmaceutical companies are often faced with a volume of content in the field that has grown to a point where the quality of that labeling is unknown. Assessment of what exists and correcting the process to avoid pitfalls in the future can be a daunting task.